Recent articles from Anastasiia
Companies Applying AI to De-Risk Clinical Trials: 2026 Watchlist
Clinical development is still shaped by a stubborn asymmetry: only around one in ten drug candidates that enter human testing ever reaches approval, and Phase II/III failures remain the biggest drivers of wasted R&D spend.
Despite growing use of …
Five Women Shaping the AI–Life Science Stack
February 11 marks the UN-designated International Day of Women and Girls in Science, established by the General Assembly in December 2015 to recognize the contributions of women in scientific fields and to encourage fuller participation across education, research, and …
Isomorphic Labs Presents an AI Drug Design Engine That Goes Beyond AlphaFold 3
On the heels of Johnson & Johnson multi-modality drug discovery collaboration last month, Isomorphic Labs has now published benchmark results for its unified AI drug design engine, the Isomorphic Labs Drug Design Engine (IsoDDE), positioning it as a unified, …
Takeda Signs $1.7B AI-Enabled Small Molecule Discovery Deal with Iambic
Takeda has entered a multi-year agreement with Iambic Therapeutics to deploy Iambic’s AI-driven small molecule discovery platform across oncology, gastrointestinal, and inflammation programs. The deal includes access to Iambic’s software and molecular design tools, with financial terms reportedly exceeding $1.7 …
Flagship’s Generate Biomedicines Eyes IPO Amid Reopening Biotech Market Window
Generate Biomedicines, a Flagship Pioneering-founded antibody platform company, has filed for an initial public offering as part of a growing wave of biotech listings in early 2026. The company has not disclosed the size or price range of the offering …
Inductive Bio Wins OpenADMET Blind Challenge With Machine Learning Models
Inductive Bio placed first in the OpenADMET-ExpansionRx blind challenge with its Beacon models, a large-scale industry competition for ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) property prediction, surpassing over 370 submissions from researchers across pharma, biotech, academia, and AI sectors.
…Anthropic, HHMI, and Allen Institute Launch Claude-Integrated AI Collaborations for Life Science Research
Anthropic has formalized partnerships with the Howard Hughes Medical Institute (HHMI) and the Allen Institute to integrate its Claude model into core scientific workflows, targeting persistent bottlenecks in experimental interpretation and hypothesis generation. The collaborations aim to embed AI agents …
Eli Lilly Strikes Up to $1.1B Gene Editing Deal with German Startup
Eli Lilly has entered a collaboration with Seamless Therapeutics worth up to $1.12 billion to co-develop gene editing therapies targeting genetic forms of hearing loss. The agreement grants Lilly exclusive rights to advance candidate therapies developed using Seamless’s recombinase-based platform, …
This AI-Ready Single-Molecule Proteomics $1.6M Grant Targets Parkinson’s Alpha Synuclein
Washington- and California-based Nautilus Biotechnology is teaming up with Weill Cornell Medicine–Qatar and the Michael J. Fox Foundation (MJFF) for Parkinson’s Research on a new research program targeting alpha-synuclein, a protein that studies suggest may be a critical driver …
Antheia Adds $24M in Series C Extension to Expand U.S. Biosynthetic Drug Manufacturing
Menlo Park–based Antheia has added $24 million in a second close of its Series C round, bringing its total raised over the past year to more than $175 million. The round was led by ATHOS KG and America’s Frontier …